Stay updated with breaking news from Market prospects. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology firm focused on innovative therapies for rare diseases, has announced favorable three-year results from the ongoing HOPE-2 open-label extension (OLE) study on CAP-1002 for Duchenne muscular dystrophy. ....